Prothena Corporation plc · NASDAQ:PRTA
Prothena — Technical Presentation (September 2020)
33 slides from Prothena's technical presentation, Sep 15, 2020
Slide 1: Prasinezumab Slows Progression on Measures of Parkinson's Disease in Phase 2 PASADENA Study
Prasinezumab Slows Progression on Measures of Parkinson’s Disease in Phase 2 PASADENA Study September 15, 2020
Slide 2: Agenda
Agenda • Introduction and Overview of Results - Gene Kinney, PhD, President & CEO • Prasinezumab Background - Wagner Zago, PhD, CSO • Phase 2 PASADENA Study Results - Radhika Tripuraneni, MD, MPH, CDO • Next Steps and Summary - Gene Kinney, PhD, President & CEO • Q&A - Gene Kinney, PhD, President &
Slide 3: Forward-looking Statements
Forward-looking Statements This presentation contains forward-looking statements. These statements relate to, among other things: the treatment potential and proposed mechanisms of action of prasinezumab; plans for the ongoing Phase 2 clinical study of prasinezumab; plans for future clinical studies
Slide 4: Introduction and Overview of Results
Introduction and Overview of Results Gene Kinney, PhD President & Chief Executive Officer
Slide 5: Prasinezumab
Prasinezumab Alpha-synuclein Immunotherapy for Parkinson’s Disease Part of Prothena’s pipeline based on expertise in protein dysregulation and focused on neurodegenerative and rare peripheral amyloid diseases Potentially disease-modifying therapy is focus of worldwide development and commercializati
Slide 6: Prothena Summary
Prothena Summary Positive clinical results from PASADENA position prasinezumab as the first potentially disease-modifying therapy for Parkinson’s disease PASADENA dataset further validates Prothena’s specific and selective targeting approach towards protein dysregulation diseases Growing and diverse
Slide 7: Phase 2 PASADENA Study
Phase 2 PASADENA Study Prasinezumab in Early Parkinson’s Disease • First potentially disease modifying, anti-alpha-synuclein antibody to demonstrate signals of efficacy on multiple pre-specified secondary and exploratory clinical endpoints, including measures of motor function and biomarkers • Slowe
Slide 8: Prasinezumab Background
Prasinezumab Background Wagner Zago, PhD Chief Scientific Officer
Slide 9: a-Synuclein Implicated in Parkinson's Disease
a-Synuclein Implicated in Parkinson’s Disease • a-synuclein pathology is strongly implicated in PD - Accumulation of a-synuclein is a predominant neuropathological feature and follows the topological progression of disease - Genetically validated target with evidence favoring a prominent role for a-
Slide 10: Summary of Effects of 9E4 in Multiple Preclinical Models of Synucleinopathy
Summary of Effects of 9E4 in Multiple Preclinical Models of Synucleinopathy Prasinezumab (murine form of 9E4) Lowering of Blockade of cell-to-cell demonstrated in multiple in vivo and a -syn Pathology transmission cellular a-synucleinopathy models to:1–4 IgG1 PRX002 IgG1 PRX002 PRX002 ü Reduce build
Slide 11: Pharmacokinetic/Pharmacodynamic Framework
Pharmacokinetic/Pharmacodynamic Framework Elements determining target- occupancy in CNS • Relative concentrations of prasinezumab Aggregated a-Syn occupancy by Monomeric prasinezumab (%) a-Syn a-Syn in peripheral and central compartments • Relative concentrations of a-synuclein in >400-fold selectiv
Slide 12: Phase 2 PASADENA Study Results
Phase 2 PASADENA Study Results Radhika Tripuraneni, MD, MPH Chief Development Officer
Slide 13: Patient Journey in Parkinson's Disease
Patient Journey in Parkinson’s Disease Stages of Parkinson’s Disease EARLY MID LATE PASADENA • Mild/moderate Treated: Treated: • Fully established motor symptoms complications • Satisfactory control of • Suboptimal control of (fluctuations and motor symptoms motor symptoms dyskinesias) • Early respo
Slide 14: PASADENA: A Phase 2 study of prasinezumab in early Parkinson's disease: Part 1 Week-52 results
PASADENA: A Phase 2 study to evaluate the safety and efficacy of prasinezumab in early Parkinson's disease: Part 1 Week-52 results Gennaro Pagano,1 Kirsten I Taylor,1,2 Judith Anzures Cabrera,3 Maddalena Marchesi,4 Wagner Zago,5 Radhika Tripuraneni,5 Anne Boulay,1 Annamarie Vogt,1 Frank G Boess,1 Ta
Slide 15: Disclosures
Disclosures Gennaro Pagano is a full-time employee and shareholder of F. Hoffmann-La Roche Ltd
Slide 16: Prasinezumab: Preclinical efficacy and proposed mode of action
Prasinezumab Preclinical efficacy and proposed mode of action Prasinezumab (PRX002/RG7935 or murine parent 9E4) demonstrated in multiple in vivo and cellular a-synucleinopathy models1–4 to: • Reduce build-up of intracellular a-Syn pathology and protect neurons • Block cell-to-cell transmission of a-
Slide 17: PASADENA Part 1: 52-week randomized, double-blind, placebo-controlled study
PASADENA Part 1 (NCT03100149): A 52-week multicenter, randomized, double-blind, placebo-controlled study Two doses versus placebo (1:1:1) Primary endpoint: Change from baseline to Week 52 in total 56 sites: US, France, Germany, MDS-UPDRS (sum of Parts I, II and III) Spain, Austria Part 1 Part 2 Key
Slide 18: Baseline characteristics
Baseline characteristics Placebo Low dose High dose All patients (n=105)* (n=105)* (n=106)* (N=316) Age, years 59.9 (8.7) 60.3 (8.8) 59.4 (9.8) 59.9 (9.1) Mean (SD) Gender, Male 71 (67.6) 71 (67.6) 71 (67.0) 213 (67.4) N (%) Disease duration 9.9 (6.8) 10.2 (6.3) 10.1 (6.5) 10.1 (6.5) Mean (SD) MAO-B
Slide 19: Overview of safety data
Overview of safety data Placebo Low dose High dose All patients (n=105) (n=105) (n=106) (n=316) Total number of AEs* 411 428 549 1388 Total number of AE with fatal outcome 0 0 0 0 (Grade 5)* Total number of patients with at least one (%):† AE 87 (82.9) 98 (93.3) 97 (91.5) 282 (89.2) SAE 5 (4.8) 7 (6
Slide 20: Primary endpoint
Primary endpoint Change in total MDS-UPDRS score (Parts I+II+III) from baseline to Week 52 MDS-UPDRS total (sum of Part I+II+III)* Placebo Pooled Low dose High dose Pooled: –1.30, 80% CI=(–3.18, 0.58); –14.0% Low dose: –2.02, 80% CI=(–4.21, 0.18); –21.5% High dose: –0.62, 80% CI=(–2.82, 1.58); –6.6%
Slide 21: Secondary endpoint
Secondary endpoint Change in total MDS-UPDRS Part III from baseline to Week 52 – Site and central rating MDS-UPDRS Part III – site rating* MDS-UPDRS Part III – central rating* Placebo Placebo Pooled Pooled Low dose Low dose High dose High dose Pooled: –1.88, 80% CI=(–3.31, –0.45); –35.0% Pooled: –1.
Slide 22: Exploratory endpoint: Time to worsening of motor function
Exploratory endpoint Time to worsening of motor function (+5 points MDS-UPDRS Part III) Placebo Pooled Cumulative Free-progression Low dose High dose Hazard ratio* comparison to placebo: Pooled: 0.82, 80% CI=0.64 to 0.99 Low dose: 0.77, 80% CI=0.63 to 0.96 High dose: 0.87, 80% CI=0.70 to 1.07 Reduce
Slide 23: Secondary and exploratory endpoints
Secondary and exploratory endpoints Change in MDS-UPDRS Part III – Bradykinesia and digital PASADENA motor score from baseline to Week 52 MDS-UPDRS Part III – Bradykinesia Digital PASADENA motor score Placebo Placebo Pooled Pooled Low dose Low dose High dose High dose Pooled: –0.75, 80% CI=(–1.62, 0
Slide 24: Secondary endpoints
Secondary endpoints a. MoCA b. CGI-I Change in Change in cognitive clinical function impression Favors prasinezumab Favors placebo Odds ratio for progressors at week 52 c. PGI-C d. DaT-SPECT Change in Change in patient’s dopaminergic Change impression terminals DaT-SPECT progression was Favors prasi
Slide 25: Exploratory endpoint
Exploratory endpoint Change in cerebral blood flow in the brain regions from baseline to Week 52 (MRI-ASL) Placebo Prasinezumab* 50 Baseline Week 52 20 N=22 N=47 Reduced decline in cerebral blood flow in the putamen *Images from a subset of all individuals treated with prasinezumab (Low/High dose).
Slide 26: Summary of results
Summary of results • The PASADENA Part 1 study did not meet its primary endpoint • Safety: Prasinezumab showed similar AEs and IRRs to placebo • Efficacy: Prasinezumab showed: ‒ Reduced decline in progression of MDS-UPDRS Part III – site and central rating and Bradykinesia subscore ‒ Reduced risk on
Slide 27: Acknowledgments
Acknowledgments We thank all participants and their families, the PASADENA investigators and the Prasinezumab Study Group for their cooperation and support with this study PASADENA investigators: Jean-Philippe Azulay, Ernest Balaguer Martinez, James Boyd, Matthew Brodsky, Anthony Ciabarra, Joseph Cl
Slide 28: Next Steps and Summary
Next Steps and Summary Gene Kinney, PhD President & Chief Executive Officer
Slide 29: Next Steps
Next Steps Potential Populations for Further Clinical Development Stages of Parkinson’s Disease EARLY MID LATE Prodromal PASADENA Early stable treated • Mild/moderate Treated: Treated: • Fully established motor symptoms complications • Satisfactory control of • Suboptimal control of (fluctuations an
Slide 30: Prothena Summary
Prothena Summary Positive clinical results from PASADENA position prasinezumab as the first potentially disease-modifying therapy for Parkinson’s disease PASADENA dataset further validates Prothena’s specific and selective targeting approach towards protein dysregulation diseases Growing and diverse
Slide 31: Protein Dysregulation
Protein Dysregulation Advancing the Scientific Landscape Optimizing the molecule (epitope matters) ⎯ Targeting appropriate epitope to optimize engagement with both soluble and insoluble pathogenic species ⎯ Engineering for optimal binding characteristics (e.g., neoepitopes, avidity optimization, etc
Slide 32: Growing Body of Clinical Evidence Supporting Targeting Proteinopathies
Growing Body of Clinical Evidence Supporting Targeting Proteinopathies Aducanumab Prasinezumab Birtamimab (NEOD001) Target: Aβ Target: Alpha-synuclein Target: Amyloid Light Chain EMERGE: Longitudinal change PASADENA Phase 2 VITAL Study All-Cause Mortality in from baseline in CDR-SB MDS-UPDRS Part II
Slide 33: Prothena's Robust Pipeline
Prothena’s Robust Pipeline Biomarker Commercial Program/Target Discovery Preclinical Phase 1 Phase 2 Phase 3 Enabled Rights Prasinezumab (PRX002/RG7935) PASADENA (Phase 2) ü MRI-ASL a-synuclein Parkinson’s Disease PRX004 misTTR ü misTTR* Phase 1 ATTR Amyloidosis Aβ Preclinical ü PET-Aβ AD Tau Precli